# Paul Grayson

> Paul Grayson is a San Diego biotechnology executive and company founder, currently President and CEO of Radionetics Oncology and Chairman of Skye Bioscience. A co-founder and former President and CEO of Tentarix Biotherapeutics, he previously held founding roles at Aurora Biosciences, Senomyx, Fate Therapeutics, and Bird Rock Bio, and worked in venture investing at Sanderling and Versant.

- **Role:** President and Chief Executive Officer at Radionetics Oncology; Chairman of the Board at Skye Bioscience
- **Organizations:** Radionetics Oncology, Skye Bioscience, Tentarix Biotherapeutics, Bird Rock Bio, Fate Therapeutics, Senomyx, Aurora Biosciences, Versant Ventures, Sanderling Ventures
- **Education:** Bachelor of Arts in Biochemistry and Computer Science, University of California, Los Angeles, Master of Business Administration, University of California, Irvine - Paul Merage School of Business
- **Known for:** Helped establish Aurora Biosciences, Senomyx, Fate Therapeutics, Bird Rock Bio, and Tentarix., Led Tentarix when it announced a $50 million Series A in 2021 and a $35 million Series B in 2023., Led Tentarix during its 2023 Gilead collaboration announcement.

## Career timeline

- **1990s** — Held a founding management role at Aurora Biosciences.
- **1999** — Founding president, CEO, and chairman of Senomyx; founder equity agreement dated February 1999.
- **2008** — Joined Fate Therapeutics as president and CEO in April after serving as managing director of Sanderling Ventures.
- **2011** — Left Fate in February to form a new company; became president and CEO of Bird Rock Bio in June.
- **2019-2020** — Partner at Versant Ventures from November 2019 to July 2020, according to Skye filings; also identified as a venture partner in Tentarix’s 2021 launch announcement.
- **2020-2023** — Co-founded Tentarix and served as president and CEO from July 2020 through November 2023.
- **2023** — Joined Skye’s board in August following its acquisition of Bird Rock Bio; became Radionetics president and CEO in November.
- **2024** — Radionetics announced his appointment publicly in January; named Skye chairman effective October 25.
- **2026** — Re-elected to Skye’s board at its May annual meeting.

## Achievements

- Helped establish Aurora Biosciences, Senomyx, Fate Therapeutics, Bird Rock Bio, and Tentarix.
- Led Tentarix when it announced a $50 million Series A in 2021 and a $35 million Series B in 2023.
- Led Tentarix during its 2023 Gilead collaboration announcement.
- Led Radionetics when it announced its July 2024 Lilly agreement, including $140 million upfront and an exclusive acquisition right priced at $1 billion.
- Appointed independent chairman of Skye Bioscience in October 2024.

## Latest updates

- **2026-05** — Re-elected as a Skye Bioscience director for a term expiring at the 2027 annual meeting.
- **2026-04** — Skye’s 2026 proxy confirmed his chairmanship, Radionetics executive role, education, and prior Tentarix tenure.
- **2024-10** — Appointed Skye chairman effective October 25, with announcement October 29.
- **2024-07** — Radionetics announced a strategic agreement with Lilly.

## Links

- Website: https://radionetics.com/team/paul-grayson/
- LinkedIn: https://www.linkedin.com/in/paul-grayson-5597a527

---

Profile page: https://yespress.io/paul-grayson
Published by YesPress — https://yespress.io
Last updated: 2026-10-15